Biliary cancer metastatic

4 trials 2 recruiting MedDRA PT
4 Registered trials
2 Recruiting
3 Unique sponsors
3 Unique IMPs
3 Commercial trials
Drug classes (ATC)
ATC code not specified 4
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Monoclonal antibody (primate) 1 substance
Phase II: 1 Phase I (Other): 1 Phase I (First in Human): 2

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase II

1 trial

Phase I (Other)

1 trial
  • Amgen Inc. Commercial
    IMP not specified
    2024-511195-33-00 8 countries 2024 n=81
    Ended

Phase I (First in Human)

2 trials
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Amgen Inc. Commercial 2 Phase I (Other), Phase I (First in Human) 0
Daiichi Sankyo Inc. Commercial 1 Phase I (First in Human) 1
Unicancer Academic 1 Phase II 1
New trials by year
2022
1
2024
1
2025
2
← All indication landscapes